The Zhitong Finance App learned that Swiss pharmaceutical giant RHHBY.US (RHHBY.US) plans to name its novel oral breast cancer drug Wilserdly and has registered this name in several jurisdictions. According to information from the US Patent and Trademark Office (USPTO), Genentech, an American subsidiary of Roche, submitted a trademark application on October 27 to register this name in capital letters, and also register a floral logo. Roche has also submitted applications for the same brand name to several regulators around the world, including the European Union Intellectual Property Office.
Zhitongcaijing · 2d ago
Share
Listen to the news
The Zhitong Finance App learned that Swiss pharmaceutical giant RHHBY.US (RHHBY.US) plans to name its novel oral breast cancer drug Wilserdly and has registered this name in several jurisdictions. According to information from the US Patent and Trademark Office (USPTO), Genentech, an American subsidiary of Roche, submitted a trademark application on October 27 to register this name in capital letters, and also register a floral logo. Roche has also submitted applications for the same brand name to several regulators around the world, including the European Union Intellectual Property Office.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending